Pfizer and Bristol stop a global trial of blood thinner apixaban

11/18/2010 | Bloomberg

Bristol-Myers Squibb and Pfizer have suspended an international, 10,800-participant study of apixaban after deciding that an increase in bleeding caused by the blood thinner outweighs clinical benefits for patients with acute coronary syndrome. "We knew there would be an increase in bleeding," a Bristol-Myers official said. "The question was whether we could achieve enough incremental efficacy to offset the incremental bleeding."

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI